Pfizer, Flagship to collaborate on obesity drug discovery

Serhii Akhtemiichuk/iStock via Getty Images Flagship Pioneering said its Pioneering Medicines and Profound Therapeutics units will collaborate with Pfizer ( NYSE: PFE ) to identify potential next-generation drug candidates for the treatment of obesity. The agreement is the first to be initiated under a previously announced strategic partnership between Pfizer and Flagship, according to a Flagship statement . Under the agreement, Flagship’s in-house drug discovery and development unit, Pioneering Medicines, will conduct foundational research with ProFound Therapeutics utilizing ProFound’s ProFoundry Platform to identify potential novel protein therapeutics from the human proteome.

Pfizer will have the option to advance selected programs under the terms of its partnership with Flagship. Flagship and Pfizer first announced their collaboration in July 2023 . More on Pfizer Pfizer Inc.

(PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates Will Boost Revenues Pfizer: Too Early For A Turnaround GSK, Pfizer to appeal Delaware ruling that allowed trials for thousands of Zantac cases Pfizer's Paxlovid ineffective in treating long COVID symptoms: study.